Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits – Genetic Engineering & Biotechnology News
|
Solid Recommits to DMD Gene Therapy on Clinical Hold, as Stock Plunge Sparks Lawsuits
Genetic Engineering & Biotechnology News Solid Biosciences restated its commitment to developing its lead candidate, the Duchenne muscular dystrophy (DMD) gene therapy SGT-001, despite the FDA's full and partial clinical holds on a Phase I/II trial for the treatment. The FDA last month … |
